Institute for Medical Epidemiology, Biometrics, and Informatics (IMEBI), Interdisciplinary Centre for Health Sciences, Medical Faculty of the Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
Department of Internal Medicine IV, Oncology/Haematology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.
Int J Infect Dis. 2023 Nov;136:14-21. doi: 10.1016/j.ijid.2023.08.019. Epub 2023 Aug 25.
The SARS-CoV-2 Omicron variant has spread rapidly and has been the dominant variant since 2022. The course of acute infection, in a vaccinated population, with Omicron is milder compared with earlier variants. However, little is known about how the occurrence of long-term symptoms after Omicron infection compared with other variants is modulated by previous infections and/or vaccinations.
Participants of the DigiHero study provided information about their SARS-CoV-2 infections, vaccinations, and symptoms 12 or more weeks after infection (post-COVID-19 condition - PCC).
Participants infected with wildtype SARS-CoV-2 had the highest PCC risk (adjusted odds ratio [aOR] 6.44, 95% confidence interval (CI): 5.49; 7.56), followed by participants infected with Alpha and Delta compared with the reference group (individuals infected with Omicron having received three or more vaccinations). Among those infected with a specific variant, the number of preceding vaccinations was not associated with a risk reduction for PCC, whereas previous infection was strongly associated with a lower PCC risk (aOR 0.14, 95% CI 0.07; 0.25).
While infection with Omicron is less likely to result in PCC compared with previous variants, lack of protection by vaccination suggests a substantial challenge for the healthcare system during the early endemic period. In the midterm, the protective effects of previous infections can reduce the burden of PCC.
SARS-CoV-2 的奥密克戎变异株已迅速传播,并自 2022 年以来成为主要变异株。与早期变异株相比,接种疫苗的人群中奥密克戎急性感染的病程较轻。然而,对于奥密克戎感染后长期症状的发生与其他变异株相比如何受到既往感染和/或接种的影响,目前知之甚少。
DigiHero 研究的参与者提供了他们的 SARS-CoV-2 感染、接种疫苗和感染后 12 周或以上(COVID-19 后状况 - PCC)的症状信息。
感染野生型 SARS-CoV-2 的参与者 PCC 风险最高(调整后的优势比 [aOR] 6.44,95%置信区间 [CI]:5.49;7.56),其次是感染 Alpha 和 Delta 的参与者与参考组(感染 Omicron 并接种了三剂或更多疫苗的个体)相比。在感染特定变异株的参与者中,先前接种疫苗的数量与 PCC 风险降低无关,而先前的感染与较低的 PCC 风险密切相关(aOR 0.14,95%CI 0.07;0.25)。
虽然与先前的变异株相比,感染奥密克戎不太可能导致 PCC,但疫苗接种缺乏保护作用表明在早期流行期间对医疗保健系统构成了重大挑战。从中期来看,既往感染的保护作用可以减轻 PCC 的负担。